Related Experiment Videos
The use of low-molecular-weight heparin in acute coronary syndromes
1University of Pennsylvania, 10 East 34th Street, Reading, PA 19606, USA.
Insights
Low-molecular-weight heparin (LMWH) plus aspirin is a safer and more effective treatment for unstable angina (USA) and non-Q-wave myocardial infarction (NQMI) than unfractionated heparin. Updated guidelines reflect these findings for acute coronary syndromes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Unstable angina (USA) and non-Q-wave myocardial infarction (NQMI) stem from atherosclerotic plaque rupture and thrombosis.
- Current treatments involve aspirin and unfractionated heparin.
Purpose of the Study:
- To evaluate low-molecular-weight heparin (LMWH) as an alternative therapy for acute coronary syndromes.
- To compare the efficacy and safety of LMWH versus unfractionated heparin in patients with USA or NQMI.
Main Methods:
- Analysis of data from two pivotal clinical trials: ESSENCE and TIMI 11B.
- Assessment of LMWH preparations in combination with aspirin for managing USA and NQMI.
Main Results:
- LMWH plus aspirin demonstrated superior effectiveness and safety compared to unfractionated heparin.
- Reduced incidence of myocardial infarction, recurrent angina, and death observed with LMWH.
Conclusions:
- LMWH represents a significant advancement in managing acute coronary syndromes.
- Updated treatment guidelines from the American College of Cardiology and American Heart Association incorporate these findings.
Abstract:
The initiating event in unstable angina (USA) and non-Q-wave myocardial infarction (NQMI) is the rupture of an atherosclerotic plaque resulting in local thrombosis. The current standard treatment is the administration of aspirin and heparin. The introduction of low-molecular-weight heparin (LMWH) offers a potential alternative therapy. Clinical trials have begun to examine the efficacy and safety of using LMWH in the management of acute coronary syndromes. Two pivotal studies have evaluated the effects of LMWH preparations on patients with USA or NQMI: The ESSENCE and the TIMI 11B trials. These studies suggest that LMWH plus aspirin is more effective and safer than unfractionated heparin in preventing myocardial infarction, recurrent angina, or death. Because of these differences, the American College of Cardiology and the American Heart Association have updated their guidelines for the treatment of USA and NQMI.